List view / Grid view
The EMA’s drug safety committee has concluded that the Janssen…
The EMA’s drug safety committee has concluded that the Janssen COVID-19 Vaccine is safe for continued use, so Johnson & Johnson will resume shipments to the EU.
After a positive recommendation from the EMA, the European Commission…
After a positive recommendation from the EMA, the European Commission has granted the single-dose vaccine conditional marketing authorisation.
If granted Emergency Use Listing by the World Health Organization…
If granted Emergency Use Listing by the World Health Organization (WHO), up to 500 million doses of Janssen’s single-dose COVID-19 vaccine could be distributed under COVAX.
J&J have submitted Phase III trial data in their application…
J&J have submitted Phase III trial data in their application to the FDA for emergency authorisation of their COVID-19 vaccine candidate.
J&J has agreed that it will supply the EU with…
J&J has agreed that it will supply the EU with 200 million doses of its COVID-19 vaccine candidate following regulatory approval.
The Canadian government has agreed that Janssen will supply the…
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
J&J will supply the US with 100 million doses of…
J&J will supply the US with 100 million doses of the company’s COVID-19 vaccine candidate following an agreement with the country's government.
The investigational SARS-CoV-2 vaccine developed by J&J is now due…
The investigational SARS-CoV-2 vaccine developed by J&J is now due to start its Phase I/IIa clinical trial at the end of July.
Developed by Janssen, the two-dose regimen has already been given…
Developed by Janssen, the two-dose regimen has already been given to 60,000 patients and now has the positive opinion of the Committee for Medicinal Products for Human Use (CHMP).
Following the selection of a COVID-19 vaccine lead, Johnson &…
Following the selection of a COVID-19 vaccine lead, Johnson & Johnson (J&J) aims to begin clinical trials in humans later this year while also scaling up its manufacturing facilities.
Johnson & Johnson announced Janssen Pharmaceutical Companies will work collaboratively…
Johnson & Johnson announced Janssen Pharmaceutical Companies will work collaboratively to screen for antiviral therapies and vaccine therapies against 2019-nCoV.
Johnson & Johnson has announced that it will be contributing…
Johnson & Johnson has announced that it will be contributing vaccines to support the Rwandan immunisation programme to combat Ebola.
